Skip to content

evERA : Giredestrant + Everolimus: evERA Biomarker Analyses | Sara Tolaney | ESMO 2026

evERA : Giredestrant + Everolimus: evERA Biomarker Analyses | Sara Tolaney | ESMO 2026

Dr. Sara TolaneyDana-Farber / Harvard

More on breast cancer

Everything on breast cancer

NATALEE 6-Year Update: Overall Survival Benefit With Ribociclib | ESMO 2026
Dr. Gil Morgan. Expert pick. ESMO 2026. Day 2.
TOP-1 Trial: Can We Omit Both Radiotherapy and Endocrine Therapy?
Dr. Elisabetta Bonzano. Expert pick. ESMO 2026. Day 2.
Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis
Publication pick. Radiotherapy & Oncology. October 15, 2026.
Advances in Systemic Treatment of Breast Cancer (Review)
Publication pick. NEJM. October 12, 2026.
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Publication pick. NEJM. October 9, 2026.
FDA NEWS: HER2CLIMB-05 Update
Regulatory news. FDA. October 7, 2026.

The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.

Email address

Your role

Your country

How we use your details